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Purpose: This cross-sectional study aimed at determining the relationship between patient-reported
quality of life (QOL) and nurse-led bedside evaluations of chemotherapy-induced peripheral neuropa-
thy symptoms.
Methods: One hundred ninety-ﬁve patients treated at the oncology clinic at our institution were assessed
using Functional Assessment of Cancer Therapy/Gynecologic Oncology GroupeNeurotoxicity and nurse-
led bedside examinations. The relationship between self-reported QOL and bedside examinations was
evaluated using Spearman rank correlations.
Results: Scores of upper and lower extremity muscle strength based on the bedside examinations
showed a weak negative correlation with the emotional well-being subscale of Functional Assessment of
Cancer Therapy-General. Further, weak negative relationships were present between QOL and the
following nurse-reported parameters: vibration perception in the hand, upper extremity muscle
strength, touch and vibration perception in the feet, and tendon reﬂexes.
Conclusion: Collectively, our results indicate that nurse-led bedside evaluation is a noninvasive and
useful method for detecting neurotoxicity and evaluating the patient’s QOL both during and after
treatment.
Copyright  2013, Korean Society of Nursing Science. Published by Elsevier. All rights reserved.Introduction
Peripheral neuropathies are among the most frequently occur-
ring and distressing adverse consequences of chemotherapy
(Nurgalieva et al., 2010), and can be caused by chemotherapeutic
agents such as taxanes, platinum compounds, and vinca alkaloids
(Ocean & Vahdat, 2004; Visovsky, 2003). Previous reports have
suggested that the incidence of chemotherapy-induced peripheral
neuropathy (CIPN) ranges from 10% to 100%, depending on certain
patient-speciﬁc factors and the speciﬁc drugs, doses, schedules, and
measurement tools (Hershman et al., 2011; Tofthagen, McMillan, &
Kip, 2011).
Although neuropathy affects the patient physically, functionally,
and psychosocially (Nielsen & Brant, 2002), CIPN has been rela-
tively neglected by physicians and nurses compared with other
chemotherapy side effects. Moreover, physicians and nurses tend to
underestimate and underreport the severity and frequency of CIPNge of Nursing, Jeju National
rea.
rean Society of Nursing Science. Psymptoms compared to the patient reports, and underestimate the
impact of the physical symptoms on the patient’s quality of life
(QOL) (Shimozuma et al., 2009). Importantly, patients may not
acknowledge or report neuropathic symptoms for fear of missing
out on an effective cancer treatment (Kaley & Deangelis, 2009).
Since the occurrence of CIPN can result in chemotherapy dose
reductions, treatment delays, and treatment discontinuation
(Visovsky, Collins, Abbott, Aschenbrenner, & Hart, 2007), CIPN
monitoring should be routinely considered in everyday practice.
However, useful tools for diagnosing and assessing toxic symptoms
and clinical practice guidelines are lacking. Currently, patient-
subjective symptoms, neurologic physical examination, nerve con-
duction velocity, vibration perception threshold, and electromyog-
raphy are themajormethods of measuring CIPN abnormalities in the
clinical setting (Hershman et al., 2011). Unfortunately, the symptoms
of neuropathies are diverse and patient-speciﬁc, making the condi-
tion difﬁcult to diagnose accurately (Visovsky & Daly, 2004). Quan-
titative neurosensory testing results are less subject to recall bias and
may play a role in further assessing and evaluating CIPN. However,
these methods can be invasive and uncomfortable for patients and
generally lack diagnostic value (Shimozuma et al., 2009).ublished by Elsevier. All rights reserved.
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comprehensive composite tools used to assess both subjective and
objective aspects of peripheral nerve function and have been tested
in patients receiving neurotoxic chemotherapy. However, because
the inclusion assessment must be performed and interpreted by a
neurologist, these instruments are too complex for use by oncology
nurses (Lavoie Smith, Cohen, Pett, & Beck, 2011). Nursing staff
should be successfully employed in collecting toxicity data after
adequate and speciﬁc training, as they are often better able to elicit
such information from patients than the medical staff and are more
accurate in describing any adverse effect of toxicity by grade (Cirillo
et al., 2009). Nurses play an important role in the early detection
and intervention of neurotoxicity, the success of treatment, and the
patient’s QOL both during and after treatment. To date, few studies
have focused on the validity of bedside assessments by nursing staff
for identifying CIPN symptoms.
This study aimed at determining the relationship between
nurse-led bedside evaluation of CIPN symptoms and patient-
reported QOL.
Methods
Setting and sample
All patients treated with at least one cycle of taxanes and/or
platinum compound agents at the inpatient ward of the oncology
clinic at Seoul St. Mary’s Hospital in South Korea between October
2010 and February 2011 were considered eligible for the current
study.Criteria forparticipantsenrolled in thestudyweremore than18
years old, a histologically conﬁrmed cancer, and a treatment plan that
included neurotoxic chemotherapeutic agents or biotherapy. Patients
with other comorbid conditions that could potentially cause CIPN,
such asdiabetesmellitus, cancers of the central nervous system, brain
metastasis, uremia, spinal injuries, and alcoholismwere excluded.
Potential participants were screened using a simple question-
naire to determine whether they had neuropathic symptoms
(numbness, tingling, pain, or impaired sensory function in hands
and/or feet, clumsiness in ﬁngers, peripheral muscular weakness,
or difﬁculties in walking). Of the 347 consecutive patients who met
the eligibility criteria, 263 patients (76%) reported at least one of the
neuropathic symptoms, while 84 patients (24%) did not report any.
Of the 263 symptomatic patients, 16 patients refused to participate
due to their poor condition. Thus, a total of 247 patients were
assessed using the National Cancer Institute Common Toxicity
Criteria (NCI CTC version 2) (Postma & Heimans, 2000). Of these
247 patients, 52 patients (21%) had a grade 0 neuropathy, and 195
patients (79%) had grade 1 or higher neuropathy (27% grade 1, 33%
grade 2, and 19% grade 3). Patients with grade 1 or higher pe-
ripheral neuropathy were enrolled in the study. More detailed in-
formation with regard to disease, treatments, QOL, and symptoms
was obtained from the 195 patients using questionnaires, medical
chart review and a nurse-led bedside examination. Using G*Power
3.1.2 (Faul, Erdfelder, Buchner, & Lang, 2009) for power analysis, the
powerwas .95 for the correlation analysis at a medium effect size of
0.30 and a signiﬁcance level of .05. The sample size of 195 was
satisfactory for identifying relationships between patient-reported
QOL and symptoms assessed by nurse-led bedside examination.
The protocol was approved by the Ethics Committee of the
Catholic University of Korea, and written informed consent was
obtained from all participants before entering the study.
Ethical consideration
The content and the method of this study were approved by the
institutional review board of the university.Measurements
Demographic andclinical characteristicswerecollectedusing self-
report measures and via medical chart review. QOL was assessed
using the Functional Assessment of Cancer Therapy (FACT)/Gyneco-
logic Oncology GroupeNeurotoxicity questionnaire (Calhoun et al.,
2003; Cella, 1997). The FACT-General (FACT-G), a 27-item self-report
questionnaire, comprises subscales assessing physical well-being,
social/family well-being, emotional well-being, and functional well-
being. The neurotoxicity subscale (11 items) was designed to mea-
sure chemotherapy-induced neuropathy (Huang, Brady, Cella, &
Fleming, 2007). Scores were calculated according to the Functional
Assessment of Chronic Illness Therapy (FACIT) manual, with higher
scores reﬂecting a better QOL. The Cronbach’s alpha of internal con-
sistency for FACT/Gynecologic Oncology GroupeNeurotoxicity, FACT-
G, and the neurotoxicity subscale was .85, .88, and .83, respectively.
Nurse-led bedside examinations were constructed with refer-
ence to the total neuropathy score, and included touch and vibra-
tion perception in the hands/feet, muscle strength of the upper/
lower extremities, and tendon reﬂexes. All measures were feasible,
noninvasive, and widely used in the clinical setting. The nurse-led
bedside examinations were conducted by two oncology nurses
(clinical experience of > 5 years) trained in peripheral nerve
function, CIPN symptoms, and assessment methods. Intra-rater
reliability for all measures ranged between .90 and .95. All 7 as-
sessments comprising the nurse-led bedside examinations were
evaluated from 0 to 4, with a higher score indicating a worse
neuropathy. A score of 0 indicated that the patient had no
neuropathy-related impairment and a score of 4 indicated excru-
ciating impairment.
Touch perception was determined based on pinprick perception
in the hands and feet using a wooden cotton swab that had been
broken to create a sharp tip. The scale was as follows: 0 ¼ normal,
1¼ reduced in the ﬁngers or toes, 2¼ reduced up to the wrist or ankle,
3 ¼ reduced up to the elbow or knee, and 4 ¼ reduced to above the
elbow or knee.
Vibratory perception was assessed using a 128-Hz tuning fork
and established techniques. Speciﬁcally, patients were asked to
close their eyes while the vibrating tuning fork was systematically
and sequentially applied to the dorsum of the interphalangeal joint
of the great toe, medial malleolus, the mid-anterior lower leg, the
patella, and the mid-anterior upper thigh. Vibratory perception in
the ﬁngertips, dorsum of the hand, wrist, forearm, and upper arm
was assessed in the same sequential fashion. Patients were asked to
describe whether they felt the vibration and/or to report when the
vibration ceased. Diminished vibratory sensation was noted if the
patient could not feel vibration at all, or if the examiner could feel
vibration from the tuning fork for a longer period than the patient
did. The vibratory perception scale was the same as that of the
touch perception scale.
Muscle strength was assessed using the manual muscle test
(Hough, Lieu, & Caldwell, 2011). The examiners screened and
assessed muscle strength of the upper extremities (bilateral
shoulder abduction, elbow ﬂexion, & wrist extension) and the
lower extremities (hip ﬂexion, knee extension, & foot dorsiﬂexion).
Muscle strength for upper/lower extremities was scored using the
following scale with the medical research council equivalent
enclosed in parentheses: 0 ¼ normal (5), 1 ¼ mild weakness
(4), 2 ¼ moderate weakness (3), 3 ¼ severe weakness (2), and
4 ¼ paralysis (0e1). If the patient would not or could not perform
the test for an individual muscle group, no score was recorded, and
data were indicated as missing. The muscle with the worse score
was used as the strength score (Hough et al.).
Tendon reﬂexes were assessed using a Babinski reﬂex hammer.
The examiners tested the Achilles tendon reﬂex. If this tendon
Table 1 Demographic and Clinical Characteristics of Participants (N ¼ 195)
Characteristics n (%) MSD or Median (range)
Age (yr) 56.9  9.7 (25e81)
 50 41 (21.0)
51e60 76 (39.0)
61e70 60 (30.8)
 71 18 (9.2)
Gender
Male 79 (40.5)
Female 116 (59.5)
Education level
 High school 140 (71.8)
 College 55 (28.2)
Marital status
Single 9 (4.6)
Married 162 (83.1)
Widowed/divorced 24 (12.3)
Current employment status
Employed 51 (26.2)
Unemployed 144 (73.8)
Subjective economic status
Good 19 (9.7)
Moderate 133 (68.2)
Poor 43 (22.1)
BMI (kg/m2)
< 18.5 11 (5.6)
18.5e22.9 86 (44.1)
 23.0 98 (50.3)
Cancer type
Lung 34 (17.4)
Colorectal malignancies 42 (21.5)
Gastric malignancies 36 (18.5)
Ovarian 32 (16.4)
Breast 21 (10.8)
Liver 12 (6.2)
Renal 6 (3.1)
Other 12 (6.2)
Cancer stage
I 2 (1.0)
II 10 (5.1)
III 67 (34.4)
IV 116 (59.5)
Chemotherapeutic agents
Platinum only 113 (58.0)
No. of cycles 6 (1e34)
Taxane only 17 (8.7)
No. of cycles 4 (2e14)
Platinum þ Taxane combined 65 (33.3)
No. of cycles 5 (1e21)
Note. BMI ¼ body mass index.
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tendon reﬂex and those of the upper extremities were tested.
Tendon reﬂexes were scored as follows: 0¼ normal; 1¼ ankle reﬂex
reduced; 2 ¼ ankle reﬂex absent; 3 ¼ ankle reﬂex absent, others
reduced; and 4 ¼ all reﬂexes absent.
Data analysis
Descriptive analyses are presented for the demographic/clinical
characteristics and the percentage of participants reporting sensory
neuropathic symptoms. Spearman rank correlation and canonical
correlation analysis were used to analyze the patient-reported
relationship between QOL and symptoms assessed by nurse-led
bedside examination. The threshold for statistical signiﬁcance
was set at .05. All data analyses were performed using SAS (version
9.1; SAS Institute, Cary, NC, USA).
Results
Demographic and clinical characteristics
The mean age of the study participants was 56.9 years. The
majority of patients were female (59.5%), married (83.1%), and
unemployed (73.8%). Most patients (77.9%) had a higher than
moderate economic status; 28.2% had a college degree, and 50.3%
were more than overweight (body mass index  23 kg/m2).
A wide range of solid tumor malignancies were represented in
the study patients, with the majority of patients having colorectal
malignancies (21.5%), gastric malignancies (18.5%), lung cancer
(17.4%), ovarian cancer (16.4%), breast cancer (10.8%), and others.
The patients were predominantly in cancer stage III (34.4%) or IV
(59.5%). One hundred and thirty participants (66.7%) received only
one neurotoxic agent, either platinum (58.0%) or taxanes (8.7%),
while 65 participants (33.3%) had received taxanes combined with
a platinum agent. The median number of chemotherapy cycles
receivedwas 6 cycles (platinum only), 4 cycles (taxanes only), and 5
cycles (platinum þ taxane) (Table 1).
QOL
Themean FACT-G scorewas 68.0 out of a maximum score of 108.
The mean score on the neurotoxicity subscale was 31.6 out of a
maximum score of 44, with the lowest QOL corresponding to
sensory domain dysfunction (Table 2).
The prevalence and severity of symptoms for each of the 11
items on the neurotoxicity subscale are shown in Figure 1.
“Numbness or tingling in the hands/feet” of the sensory domain,
and “weak all over” and “trouble walking” of the motor domain
were themost common symptoms. Patients mentioned that among
neurotoxicity symptoms, “numbness or tingling in feet” (39%),
“weak all over” (36%), “numbness or tingling in hands’” (33%), and
“trouble buttoning buttons” (31%) had a severe, negative impact on
their QOL.
Outcomes of nurse-led bedside examination
Nurse-led bedside examinations were performed to assess CIPN.
Fourteen patients (7.2%) scored 1 or higher in the hand perception
of touch, and 6 patients (3.1%) scored 1 or higher in the hand
perception of vibration. Sixty-eight patients (34.9%) scored 1 or
higher in the foot perception of touch. Of these 68 patients, 5 (2.6%)
scored 3. In the foot perception of vibration, 76 patients (39.0%)
scored 1 or higher. Of these, 27 patients (13.8%) scored 3. In the
upper extremity muscle strength test, 27 patients (13.8%) scored 1
or higher, and in the lower extremity muscle strength test, 28patients (14.4%) scored 1 or higher. In the tendon reﬂex test, 83
patients (42.6%) scored 1 or higher, although none showed serious
damage with a score of 3 or higher (Table 2).
Relationship between QOL and nurse-led bedside symptom
evaluations
Scores of upper/lower extremity muscle strength based on
nurse-led bedside examinations showed a weak negative correla-
tion with the emotional well-being subscale of FACT-G. Our results
indicated that weak negative relationships were present between
the perception of vibration in the hands and the QOL affected by
“trouble buttoning buttons”; between upper muscle strength and
QOL affected by feeling “weak all over”; between touch perception
in the feet and QOL affected by “numbness or tingling in hands or
feet,” “discomfort in hands,” “trouble walking,” and “trouble
buttoning buttons”; between perception of vibration in the feet and
QOL affected by “numbness or tingling in hands,” “numbness or
tingling in feet,” “discomfort in feet,” and “trouble walking”; and
between tendon reﬂex and QOL affected by “numbness or tingling
in feet, discomfort in feet” and “trouble walking” (Table 3).
Table 2 Quality of Life Related to CIPN of Participants and Outcomes of Nurse-
led Bedside Examination (N ¼ 195)
FACT/GOG-Ntx (possible range) M  SD
FACT-G total score (0e108) 68.0  17.5
Physical well-being (0e28) 17.1  7.4
Social/family well-being (0e24) 18.6  4.8
Emotional well-being (0e28) 17.2  4.8
Functional well-being (0e28) 15.1  5.5
Neurotoxicity subscale (0e44) 31.6  8.3
Sensory (0e4) 2.4  1.2
Hearing (0e4) 3.5  0.7
Motor (0e4) 2.6  1.0
Dysfunction (0e4) 3.6  0.7
Type of bedside
examination
Scores, n (%)a
0 1 2 3
Hands touch sensibility 181 (92.8) 9 (4.6) 5 (2.6) 0 (0.0)
Hands vibration sensibility 189 (96.9) 1 (0.5) 4 (2.1) 1 (0.5)
Feet touch sensibility 127 (65.1) 9 (4.6) 54 (27.7) 5 (2.6)
Feet vibration sensibility 119 (61.0) 10 (5.1) 39 (20.0) 27 (13.9)
Upper extremity muscle
strength
168 (86.1) 21 (10.8) 6 (3.1) 0 (0.0)
Lower extremity muscle
strength
167 (85.6) 21 (10.8) 6 (3.1) 1 (0.5)
Tendon reﬂexes 112 (57.5) 77 (39.4) 6 (3.1) 0 (0.0)
Note. CIPN ¼ chemotherapy-induced peripheral neuropathy; FACT/GOG-
Ntx ¼ Functional Assessment of Cancer Therapy/Gynecologic Oncology
Group-Neurotoxicity; FACT-G ¼ FACT-General.
a No scores of 4 were observed among patients in the study.
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overall relationship between the patients’ perceived QOL and the
nurse-led bedside examination scores, yielded ﬁve canonical
functions. The canonical correlation coefﬁcient of canonical func-
tion 1 was .472, and was statistically signiﬁcant. The relationship
between the seven nurse-led bedside examinations (independent
variables) and the ﬁve subscales of the QOL measure (dependent
variables) was examined with respect to the canonical loadings 
0.30. Results showed that among the nurse-led bedside examina-
tions, feet vibration sensibility had the highest correlation with
QOL scores, followed by tendon reﬂexes. Among the QOL subscales
the neurotoxicity subscale showed a high correlation with the
nurse-led bedside examination scores (Table 4).Figure 1. The prevalence and severity of symptDiscussion
In this study, we provided evidence that nurse-led bedside CIPN
symptom evaluation can be a valuable tool for assessing patient
symptoms and QOL.
The NCI-CTC neurotoxicity scale is commonly used to quantify
neuropathy signs and symptoms, although it has been criticized for
poor reliability and suboptimal sensitivity (Lavoie Smith et al.,
2011). Here, 79% (n ¼ 195 of the total 247 patients) of the initial
enrollment participants were considered to be grade 1 or higher on
the NCI-CTC neurotoxicity scale. The scale grading is based on
whether a symptom interferes with function (grade 2), with daily
life activities (grade 3), or permanently interferes with function or
causes paralysis (grade 4). In the present study, only cases with an
NCI-CTC grade 1 or higher were analyzed. During initial enrollment,
21% of the enrolled patients were classiﬁed as grade 0, and were
determined to be normal by the NCI-CTC assessment performed by
the nurses, even though the patients indicated experiencing more
than one CIPN symptom on the questionnaire. These ﬁndings
suggest that in CIPN assessment simply asking patients about the
existence of neuropathy should be considered as important as so-
phisticated testing (Armstrong, Almadrones, & Gilbert, 2005).
Among the CIPN symptoms, “numbness or tingling in feet,”
“weak all over,” “numbness or tingling in hands,” and “trouble
buttoning buttons”were the symptoms the participants mentioned
as signiﬁcantly lowering their QOL. Typically, sensory domain
dysfunction on the neurotoxicity subscale had the most negative
impact on patients’ QOL, while “numbness or tingling in the hands/
feet” of the sensory domain and feeling “weak all over” and
“trouble walking were the most common symptoms of the motor
domain. The rates of these symptoms were higher than those re-
ported in the study by Hershman et al. (2011), where 27% and 25%
of breast cancer patients who underwent chemotherapy reported
severe numbness in the hands and feet, respectively. Numbness in
the hands and feet was the most common symptoms, and patients
may have difﬁculty adjusting to this chronic loss of sensation. In-
juries such as burns, blisters, and falls are likely to occur from a
combination of diminished sensation, weakness, and loss of pro-
prioception and balance (Tofthagen, McAllister, & McMillan, 2011).
Nonetheless, our results are consistent with those in prior studiesoms of neurotoxicity subscale (11 items).
Table 3 Correlation between Quality of Life and Nurse-led Bedside Examination (N ¼ 195)
Quality of life Nurse-led bedside examinationa
Hands touch Hands vibration Feet touch Feet vibration Upper strength Lower strength Tendon reﬂexes
FACT-G total score
Physical well-being e e e e e e e
Social/family well-being e e e
Emotional well-being e e e e 0.21* 0.21* e
Functional well-being e e e e e e e
Neurotoxicity subscale
Sensory
Numbness or tingling in hands e e 0.23* 0.23* e e e
Numbness or tingling in feet e e 0.23* 0.37* e e 0.32*
Discomfort in hands e e 0.21* e e e e
Discomfort in feet e e e 0.33* e e 0.31*
Hearing
Trouble hearing e e e e e e e
Ringing or buzzing in ears e e e e e e e
Motor
Joint pain or muscle cramps e e e e e e e
Weak all over e e e e 0.20* e e
Trouble walking e e 0.20* 0.24* e e 0.29*
Dysfunction
Trouble buttoning buttons e 0.27* 0.23* e e e e
Trouble feeling the shape of small objects e e e e e e e
Note. FACT-G ¼ Functional Assessment of Cancer TherapyeGeneral.
*p < .05.
a Values are Spearman rank correlation coefﬁcient (r) and “e“ indicates no statistically signiﬁcant correlation means.
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more severe than motor impairments, and that the lower extrem-
ities usually show symptoms earlier than the upper extremities.
Hausheer, Schilsky, Bain, Berghorn, and Lieberman (2006) hy-
pothesized that the relative sparing of motor neurons occurs
because these neurons are more heavily myelinated, and the upper
and lowermotor neuron cell bodies are protected in the spinal cord.
The longer axons are the ﬁrst ones to be affected. Thus, the sensory
changes affect the tips of the toes, followed by the ﬁngers, and
progresses proximally to the ankles andwrists in a “stocking-glove”
manner.
Motor-related symptoms are uncommon compared to sensory-
related symptoms. However, loss of sensation and weakness in theTable 4 Predicting Quality of Life from Nurse-led Bedside Examinations
Using Canonical Correlation Analysis
Variables CF1
CL
Independent variables
Nurse-led bedside examination
Feet vibration sensibility .364*
Tendon reﬂexes .349*
Hands vibration sensibility .266
Hands touch sensibility .263
Feet touch sensibility .251
Lower extremity muscle strength .047
Upper extremity muscle strength .030
Dependent variables
Quality of life
Neurotoxicity subscale .425*
Functional well-being .275
Physical well-being .189
Social/family well-being .127
Emotional well-being .117
Canonical correlation ¼ .472
Canonical root (R2) ¼ .231
Redundancy Index ¼ .066
Wilks’s lambda ¼ .670
p < .001
Note. CF ¼ canonical function; CL ¼ canonical loading.
*CL  .30.muscles of the lower extremities are common symptoms of pe-
ripheral neuropathy, regardless of etiology (Tofthagen, Overcash, &
Kip, 2012). Loss of ﬂexibility and strength can cause further im-
pairments and disability. Here, muscle weakening in the lower and
upper extremities was similar. Based on the patient-reported QOL
results, weakening of the hand muscles made delicate movements,
such as buttoning buttons, difﬁcult, and weakening of the feet
muscles led to feeling “weak all over” or “trouble walking,” thereby
negatively affecting QOL.
Loss of tendon reﬂexes, especially ankle jerks can appear as the
ﬁrst sign of CIPN (Kaley & Deangelis, 2009). Reduction in tendon
reﬂexes is caused by impairment of the afferent or efferent limbs of
the reﬂex arc. The tendon reﬂex represents the function of not only
the motor system, but also deep sensation (Ohsumi & Sunada,
2004). Lavoie Smith et al. (2011) reported that tendon reﬂexes
should be assessed, but inclusion in the reduced version of total
neuropathy score is not recommended because tendon reﬂex
scores differ by chemotherapy dosage, whereas pin sensibility and
strength scores do not. However, it is not easy for an inexperienced
nurse to observe the tendon reﬂex response even in patients
without neurologic disorders. Education and experience are
required to test tendon reﬂexes, which can be achieved through
time and practice (Ohsumi & Sunada).
In this study, the level of emotional well-being subscale of the
FACT-G was also lower with weaker upper/lower extremity muscle
strength. This likely occurred because weak upper extremity
muscle strength makes everyday activities difﬁcult, while weak
lower extremity muscle strength can limit movement. Thus, weak
extremity muscle strength may cause difﬁculties in maintaining an
independent lifestyle and lead to low self-esteem and stress. The
neurotoxicity subscale scores also mildly correlated with scores
from the bedside symptom assessment (e.g., hands vibration
perception). Additionally, we found the muscle strength test was
effective in assessing and evaluating the impact that damages to the
upper extremities have on QOL, while the touch/vibration percep-
tion and tendon reﬂex tests were effective for the lower extrem-
ities. Additionally, we veriﬁed that among the nurse-led bedside
examinations, feet vibration sensibility, followed by tendon re-
ﬂexes, had the highest predictive power for QOL, and among the
Y.-S. Yoo, O.-H. Cho / Asian Nursing Research 8 (2014) 36e41 41QOL subscales, the neurotoxicity subscale had the highest predic-
tive power.
This study had several limitations. Since this was a cross-
sectional study, we were not able to conﬁrm the sensitivity of
changes in CIPN otherwise possible in longitudinal studies. More-
over, we were unable to distinguish symptoms from aging and
those from illnesses other than cancer, or accurately control for
the effect of accumulation of chemotherapeutic agents. Further
research is necessary to determine barriers to nurses conducting
bedside examinations and their proﬁciency. Identifying the asso-
ciation between nurse-led bedside examination and advanced ex-
amination (e.g., laboratory tests, nerve conduction studies) is also
necessary.
Conclusion
The self-reported FACT/Gynecologic Oncology GroupeNeuro-
toxicity scores mildly correlated with the scores from the nurse-led
bedside examination (feet touch sensibility, feet vibration sensi-
bility, and tendon reﬂex), although the validity of the nurse-led
bedside examination could not be veriﬁed.
The nurse-led bedside examination for CIPN assessment and
evaluation is feasible and can be easily performed in the clinical
setting. Bedside examination measurements should be carefully
selected based on the available evidence to ensure high validity and
could potentially become the primary tool for CIPN symptom
assessment in the clinical setting. Standardization of clinical
assessment and development of structured recording checklist
procedures to enhance accuracy will also be essential to ensure
greater precision in these bedside measurements.
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